Xtant Medical Holdings, Inc.
AMEX:XTNTMedical - Devices
-$0.00 today
- Market cap
- $50.37M
- Beta
- -0.17
- P/E (TTM)
- 33.4
- EPS (TTM)
- $0.01
Volume 0.16M
Average 0.16M
XTNT Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Xtant Medical Holdings, Inc.AMEX: XTNT
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns positive
Q1 FY2026 accounts receivables was $444K, compared with -$3.11M a year earlier. Trailing-twelve-month accounts receivables was $2.97M. Over 3 fiscal years it compounded at -46.9% a year.
Context
- Accounts receivables amounted to 0.4% of revenue in FY2025, down 0.2 pp from a year earlier.
- Accounts receivables grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near $444K or moves back toward the trailing-twelve-month quarterly average of $741.75K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (591K) USD
- Year-over-year change
- +21.7%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (591K) | +21.7% |
| FY2024 | 2024-12-31 | (755K) | +91.4% |
| FY2023 | 2023-12-31 | (8.74M) | -121.7% |
| FY2022 | 2022-12-31 | (3.94M) | -1135.4% |
| FY2021 | 2021-12-31 | (319K) | — |
Accounts Receivables vs competitors
How XTNT compares with its peers on the latest reported figures
- XTNT's LTM Mar 2026 accounts receivables of $2.97M is the 3rd largest of the 8 companies compared; the peer median is $631K.
- Its year-over-year change of +199.2% is the 2nd highest of 8, against a peer median of -63.8%.
- Accounts receivables amounts to 2.4% of revenue for XTNT, versus a peer median of 5.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.22M | -27.6% | +17.3% | 6.9% | |
| LTM Mar 2026 | $3.09M | +162.7% | — | 4.3% | |
| LTM Mar 2026 | $2.97M | +199.2% | -46.9% | 2.4% | |
| LTM Mar 2026 | $1.84M | -561.0% | — | 5.4% | |
| LTM Mar 2026 | $1.31M | -404.9% | — | 2.3% | |
| LTM Mar 2026 | $631K | +5158.3% | — | 12.3% | |
| LTM Mar 2026 | $522K | -769.2% | — | — | |
EXOZeXoZymes, Inc. | LTM Mar 2026 | $187.09K | -63.8% | — | — |
| Peer median (excluding XTNT) | $631K | -63.8% | +17.3% | 5.4% | |
Competitors are the stored peer set for XTNT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (4.85M) | (8.49M) | 660K | (16.45M) | 4.97M |
| Depreciation & Amortization | 1.33M | 1.29M | 3.17M | 4.22M | 5.22M |
| Deferred Income Tax | 0 | 0 | (1.9M) | 21K | 0 |
| Stock-Based Compensation | 2.21M | 2.46M | 2.74M | 4.12M | 2.89M |
| Change in Working Capital | 793K | (2.81M) | (3.63M) | (5.35M) | (3.05M) |
| Accounts Receivables | (319K) | (3.94M) | (8.74M) | (755K) | (591K) |
| Inventory | 2.62M | (1.15M) | (1.89M) | (2.49M) | (2M) |
| Accounts Payables | (332K) | 875K | 2.98M | 1.03M | (3.12M) |
| Other Working Capital | (1.18M) | 1.41M | 4.01M | (3.13M) | 2.66M |
| Other Non-Cash Items | 954K | 2.2M | (10.55M) | 1.54M | 2.5M |
| Operating Cash Flow | 439K | (5.34M) | (9.52M) | (11.9M) | 12.55M |
| Capital Expenditures | (2.12M) | (1.76M) | (1.46M) | (4.11M) | (2.38M) |
| Acquisitions (Net) | 0 | 0 | (23.5M) | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 225K | 205K | 175K | 383K | 10.28M |
| Investing Cash Flow | (1.89M) | (1.56M) | (24.78M) | (3.73M) | 7.9M |
| Debt Repayment | (592K) | (291K) | 6.18M | 12.43M | (9.33M) |
| Common Stock Issued | 18.43M | 9.31M | 14.01M | 4.46M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (65K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (337K) | 9.07M | (500K) | (816K) | (175K) |
| Financing Cash Flow | 17.5M | 9.02M | 19.69M | 16.07M | (9.57M) |
| Effect of Forex Changes | 0 | 0 | 24K | (149K) | 232K |
| Net Change in Cash | 16.05M | 2.12M | (14.58M) | 298K | 11.11M |
| Free Cash Flow | (1.68M) | (7.11M) | (10.97M) | (16.01M) | 10.16M |
Xtant Medical Holdings, Inc.
AMEX:XTNT
Intrinsic Alpha fair value
Locked
Current Price
$0.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.